Primary Objective: To demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product Dermacyd PHDESILSTYFR.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
55
Treatment duration: 6 weeks
Sanofi-Aventis Administrative Office
São Paulo, Brazil
Evaluation of the absence of primary and accumulated dermical irritability and dermical sensitivity by using International Contact Dermatitis Research Group (ICDRG) scale.
Time frame: From the treatment start to the end of the study( treatment period 6 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.